Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (251-260 of 290) with videos related to

Pageof 29
Sort By:
Future Oncology (London, England)|October 12, 2021
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPCOliver Sartor, Daniel George, Bertrand Tombal, et al.
NEJM Evidence|March 25, 2025
A Randomized Trial of an App-Based Therapeutic for Lower Urinary Tract SymptomsChristian Gratzke, Sandra Schönburg, Sven Eger, et al.
European Urology Focus|June 9, 2024
App-based Therapy of Erectile Dysfunction Using a Digital Health Application (EDDIG Study): A Randomized, Single-blind, Controlled TrialSabine Kliesch, Jann-Frederik Cremers, Claudia Krallmann, et al.
BMC Nephrology|February 6, 2019
Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancerJan Ebbing, Felix Menzel, Paolo Frumento, et al.
The Journal of Urology|November 18, 2008
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detectionMartin Schostak, Gerhard P Schwall, Slobodan Poznanović, et al.
Cancer|February 10, 2024
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)Celestia S Higano, Sabina Dizdarevic, John Logue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling timeMatthew R Smith, Fred Saad, Stephane Oudard, et al.
Scientific Reports|June 1, 2018
Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancerJan Ebbing, Robin Colja Heckmann, Justin William Collins, et al.
BJU International|June 25, 2020
Transurethral en bloc submucosal hydrodissection vs conventional resection for resection of non-muscle-invasive bladder cancer (HYBRIDBLUE): a randomised, multicentre trialGeorgios Gakis, Alexander Karl, Simone Bertz, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Pageof 29

Showing results (251-260 of 290) with videos related to

Sort By:
Pageof 29
Future Oncology (London, England)|October 12, 2021
Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPCOliver Sartor, Daniel George, Bertrand Tombal, et al.
NEJM Evidence|March 25, 2025
A Randomized Trial of an App-Based Therapeutic for Lower Urinary Tract SymptomsChristian Gratzke, Sandra Schönburg, Sven Eger, et al.
European Urology Focus|June 9, 2024
App-based Therapy of Erectile Dysfunction Using a Digital Health Application (EDDIG Study): A Randomized, Single-blind, Controlled TrialSabine Kliesch, Jann-Frederik Cremers, Claudia Krallmann, et al.
BMC Nephrology|February 6, 2019
Outcome of kidney function after ischaemic and zero-ischaemic laparoscopic and open nephron-sparing surgery for renal cell cancerJan Ebbing, Felix Menzel, Paolo Frumento, et al.
The Journal of Urology|November 18, 2008
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detectionMartin Schostak, Gerhard P Schwall, Slobodan Poznanović, et al.
Cancer|February 10, 2024
Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)Celestia S Higano, Sabina Dizdarevic, John Logue, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling timeMatthew R Smith, Fred Saad, Stephane Oudard, et al.
Scientific Reports|June 1, 2018
Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancerJan Ebbing, Robin Colja Heckmann, Justin William Collins, et al.
BJU International|June 25, 2020
Transurethral en bloc submucosal hydrodissection vs conventional resection for resection of non-muscle-invasive bladder cancer (HYBRIDBLUE): a randomised, multicentre trialGeorgios Gakis, Alexander Karl, Simone Bertz, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2022
Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study)Daniel J George, Neeraj Agarwal, Oliver Sartor, et al.
Pageof 29